2013-04-11 07:33:57 -
Medigene AG /
Medigene Announces Results from Investigator Initiated Trial of EndoTAG®-1 to be
Published for ASCO 2013
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, April 11, 2013. Medigene AG (Frankfurt, Prime Standard; MDG)
announced today that the results from the Phase 2 investigator initiated trial
(IIT) of EndoTAG(®)-1 in HER2-negative breast cancer will be published for the
upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The
abstract (#114428), entitled "Feasibility study of cationic liposome-
encapsulated paclitaxel in combination with paclitaxel followed by FEC as
induction therapy in
HER2-negative breast cancer" was chosen for inclusion
online in the ASCO 2013 Annual Meeting Proceedings, a Journal of Clinical
Oncology supplement, and will be released at www.asco.org on May 15, 2013.
The investigator initiated trial with EndoTAG(®)-1 was conducted by Prof. Dr.
Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in
Brussels, Belgium, and principal investigator in the previously conducted
EndoTAG(®)-1 phase II trial in locally relapsed and/or metastatic advanced
Triple Negative Breast Cancer (TNBC). The aim of the exploratory open-label
Phase 2 IIT was to evaluate the efficacy and safety of neoadjuvant EndoTAG(®)-1
in combination with paclitaxel in patients with HER2-negative breast cancer.
About EndoTAG(®)-1: EndoTAG(®)-1 is a novel composition of the established
cytostatic drug paclitaxel combined with neutral and positive lipids. The
positively charged lipids imply that EndoTAG(®)-1 interacts with newly
developed, negatively charged endothelial cells, which are primarily required
for the growth of tumor blood vessels. The EndoTAG(®)-1 paclitaxel component
attacks the endothelial cells as they divide, thus targeting the blood supply to
tumors without affecting the supply to healthy tissue. By doing this,
EndoTAG(®)-1 is expected to prevent the formation of new tumor blood vessels and
to inhibit tumor growth. Medigene has successfully completed two clinical phase
II trials of EndoTAG(®)-1 in the indications pancreatic cancer and triple-
negative breast cancer (TNBC).
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from a
marketed product (Veregen(®)), which is distributed by partner companies.
Medigene has two drug candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®),
and is developing an innovative vaccine technology. For more information, please
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to
Press release as PDF:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE